Background and Objective: The emergence of multidrug-resistant (MDR) bacteria poses a significant global health threat, necessitating the discovery of new antimicrobial agents. The objective of this study was to isolate, purify and characterize antibacterial compounds from the endophytic actinomycete Streptomyces mutabilis AL024 and to evaluate their potential as novel drug candidates. Materials and Methods: Antibacterial activity of the isolated compounds was investigated in vitro against a panel of Gram-positive and Gram-negative bacteria, including different strains of Methicillin-resistant Staphylococcus aureus (MRSA). The compounds were further analyzed for their molecular interactions with key bacterial proteins using in silico molecular docking simulations with SwissDock. Results: Two purified compounds, identified as actinomycins V and D, demonstrated potent antibacterial activity against all tested bacterial strains. The molecular docking results corroborated these findings, revealing that both actinomycins V and D possessed a high binding affinity for the selected protein targets. The analysis indicated that actinomycin V formed more hydrogen bonds and exhibited a stronger binding affinity than actinomycin D. These interactions suggest that the compounds’ mechanism of action involves inhibiting critical metabolic enzymes essential for bacterial growth and survival. Conclusion: This study provides compelling evidence that actinomycins V and D from Streptomyces mutabilis AL024 have significant antibacterial potential. The combined in vitro and in silico findings validate their efficacy and offer a promising basis for future research into their development as new antibacterial drugs to combat drug-resistant infections.